Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
TINDAMAX (tinidazole) is an oral nitroimidazole antimicrobial approved in 2004 for the treatment of parasitic and protozoal infections. It works by disrupting DNA synthesis in susceptible organisms, making it effective against infections such as amebiasis, giardiasis, and trichomoniasis. The drug is administered as an oral tablet and is used for both acute treatment and eradication of certain infections.
As LOE approaches, brand team focus will shift from growth initiatives to lifecycle management and potential generic transition strategies.
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Treatment of Bacterial Vaginosis With Oral Tinidazole
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TINDAMAX positions professionals in a mature, stable product portfolio with emphasis on commercial efficiency and market access rather than innovation. The LOE trajectory offers experience in lifecycle management, generic transition planning, and competitive defense strategies valuable for career development in pharmaceutical operations.